Drug intelligence / Profile preview

USL

Development stage: Phase 2
Administration: Ophthalmic

Overview

USL is an investigational drug currently in Phase 2 development for the treatment of Dry Eye Disease. The objective of the ongoing clinical trial is to evaluate its efficacy and safety, and to determine the appropriate dosage. The study is designed as a dose-finding, double-blind, randomized placebo-controlled trial.

Beyond the preview

Go deeper on USL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USL.

Explore the full profile